Introduction
Genetically engineered mice are providing valuable information regarding the functions of proteins in the retina and choroid, and their role in various ocular diseases. [1] [2] [3] [4] [5] [6] [7] [8] [9] This has helped to identify targets for therapeutic intervention and has suggested possible pharmacological uses for proteins. Gene therapy provides a good way to achieve sustained delivery of proteins. Numerous preclinical studies using gene transfer with viral vectors have provided proof of concept for gene-based therapies in the eye, [10] [11] [12] [13] [14] [15] [16] [17] and there are two ongoing clinical trials utilizing adenoviral vectors, one in babies with retinoblastoma and the other in patients with neovascular age-related macular degeneration. 18 The potential applications for viral vectors in the eye are enormous and should be pursued, but there are still important hurdles that must be overcome such as immune reactions and difficulties in production and quality control. Nonviral vectors provide a complementary approach for which production is much easier and immune reactions can be minimized, but the therapeutic use of nonviral vectors is limited by poor transduction efficiency compared to viral vectors. Parallel development of both viral and nonviral vectors would seem to be the most prudent approach.
The transduction efficiency of nonviral vectors can be substantially improved in some tissues by electroporation (for a review, see Somiari et al 19 ) . Electroporation is the use of electric fields to facilitate penetration of macromolecules into cells; it is based upon the observation that electric fields can alter the structure and permeability of cell membranes. 20 Electroporation has been used extensively for gene transfer in vitro, and since the early 1990s, it has also been used for gene delivery in vivo. [21] [22] [23] The first application for the eye was for gene delivery to the cornea, 24, 25 but recently electroporation has been used to deliver genes to retinal ganglion cells in adult rat retina 26, 27 and to retinal progenitor cells in neonatal rodents. 28 Lipofection is another strategy first used for gene transfer in vitro, 29 and more recently adapted to gene delivery in vivo. [30] [31] [32] [33] Cationic lipids condense DNA protecting it from degradation, facilitate endocytosis, and, in many instances, promote breakdown of endosomal membranes to release DNA into the cytoplasm. Lipofection has been used for systemic delivery of DNA, 32, 33 and has also been used to target specific organs such as the lung 30 and brain. 31 In this study, we explored the use of electroporation and lipofection for gene transfer to retina and periocular tissue in vivo.
Materials and methods

Plasmids
The plasmid pRc/CMV-LacZ was obtained from Invitrogen (Carlsbad, CA, USA) and the placF plasmid has been previously described and characterized. 34, 35 The À585 to +38 bp 5 0 -upstream fragment of the vitelliform macular dystrophy (VMD2) gene, which selectively drives reporter gene expression in retinal pigmented epithelial (RPE) cells in transgenic mice, was inserted into the placF plasmid upstream of a LacZ gene yielding pLacF/VMD2-LacZ. 35 For injections, plasmids were suspended in PBS, OMEM (Invitrogen) containing 400 ml/ml of Lipofectamine2000 (Lf) (Invitrogen), or OMEM containing 100 ml/ml of NeuroPorter (Np) (Gene Therapy Systems, San Diego, CA, USA). Mixtures of plasmids and lipidcontaining media were incubated for 20 min at room temperature before injection.
Plasmid injections
Adult (6-8 weeks old) Balb/C mice were treated humanely in strict compliance with the Association for Research in Vision and Ophthalmology statement on the use of animals in research. Intravitreous and subretinal injections were carried out with a Harvard pump apparatus and pulled glass micropipettes as described previously. 11 Micropipettes were calibrated to deliver 1 ml of vehicle upon depression of a foot switch. For intravitreous injections, mice were anesthetized, pupils were dilated, and under a dissecting microscope, a sharpened tip of a micropipette was passed through the sclera just behind the limbus into the vitreous cavity and the foot switch was depressed. Subretinal injections were performed using a condensing lens system on the dissecting microscope and a fragment of coverslip that served as a contact lens and allowed visualization of the retina during the injection. A pipette tip was passed through the sclera posterior to the limbus and positioned just above the retina. Depression of the foot switch caused a jet of injection fluid to penetrate the retina. This technique is very atraumatic and the direct visualization allows confirmation of successful subretinal injection by the appearance of a small retinal detachment (bleb). The blebs were quite uniform in size and involved about 1/4 of the retina. For periocular injections, a 32-G needle of a Hamilton syringe was inserted beneath the conjunctiva, and 10 ml were injected.
Electroporation
When combined with intraocular injection of a plasmid, two steel electrodes separated by about 3.0 mm were placed on the eye such that the plus electrode contacted the sclera posteriorly near the location of the injection and the minus electrode contacted the sclera on the other side of the eye. When combined with periocular injection of a plasmid, electrodes separated by about 2.0 mm were placed parallel on the conjunctiva on each side of the injection site. An ECM830 electroporator (BTX, San Diego, CA, USA) was used to deliver eight 50 ms pulses separated by 100 ms with voltage set at 10, 20, or 30 V.
Histochemistry
Mice were euthanized and eyes were removed and fixed in 2% paraformaldehyde, and 0.2% glutaraldehyde in phosphate-buffered saline (PBS) for 1 h. Fixed eyes were rinsed twice in PBS, incubated in X-gal solution for 6 h (unless stated otherwise), and postfixed with 4% paraformaldehyde in PBS for 30 min. After rinsing with PBS, whole eyes were photographed with a Nikon Digital Still Camera DXM1200 (Nikon Instruments Inc., New York, NY, USA). Eyes were then embedded in optimal cutting temperature embedding compound (OCT; Miles Diagnostics, Elkhart, IN, USA). Ocular frozen sections were rinsed in deionized water, counterstained with NUCLEAR FAST RED (Vector Laboratories Inc., Burlingame, CA, USA), and dehydrated in a step gradient of 70 and 100% ethanol, and xylene. Sections were mounted in Cytoseal XYL mounting medium (Richard-Alan Scientific, Kalamazoo, MI, USA), examined with an Axioskop microscope (Zeiss, Thornwood, NY, USA), and photographed. In order to examine retinal morphology in greater detail in some eyes, the anterior segments were removed and the posterior eyecups were fixed in 4% paraformaldehyde, washed with 6.8% sucrose, dehydrated in a step gradient of 25, 50, and 75% ethanol, and embedded in cold-polymerizing resin Technovit 8100 (Heraeus Kulzer GmbH & Co., Wehrheim, Germany) according to the manufacturer's instructions. In all, 1 mm serial sections were cut, stained with Toluidine Blue, and examined with an Axioskop microscope.
Recording and analysis of electroretinograms (ERGs)
An Espion ERG Diagnosys (Diagnosys LLL, Littleton, MA, USA) was used to perform ERGs as described previously. 9 Mice were dark-adapted for a standardized 12-h period overnight and ERG recordings were performed in dim red light illumination. Beginning at the same time each morning, mice were anesthetized by intraperitoneal injection of 25 ml/g body weight of Avertin (Aldrich, Milwaukee, WI, USA) diluted 1:39 in PBS. Corneas were anesthetized with a drop of 0.5% proparacaine hydrochloride (Alcon Labs, Ft. Worth, TX, USA) and pupils were dilated with 1% tropicamide. Mice were placed on a pad heated to 391C and platinum electrodes were placed on each cornea after application of gonioscopic prism solution (Alcon Labs). The reference electrode was placed subcutaneously in the anterior scalp between the eyes, and the ground electrode was inserted into the tail. Electrode impedance was balanced for each eye pair measured. The head of the mouse was placed in a standardized position in a ganzfeld bowl illuminator that assured equal illumination of the eyes. Simultaneous recordings from both eyes were made for 11 intensity levels of white light ranging from -3.00 to +1.40 log cd-s/ m 2 . The Espion ERG machine measures the ERG response six times at each flash intensity and records the average value.
Results
Electroporation or lipid carrier promote transfer of plasmid DNA from the subretinal space into RPE cells Staining for LacZ was carried out on several eyes at various time points after injection of plasmid in different vehicles with and without electroporation. At 3 days after subretinal injection of 0.5 mg of pRc/CMV-LacZ in 1 ml of aqueous medium, there was no identifiable . In contrast, in six of six eyes evaluated 3 days after subretinal injection of the same amount of plasmid combined with electroporation with a power of 10 V/mm, there was staining for LacZ. Figure 1c shows one of the eyes demonstrating strong, but not uniform, staining throughout the region where the retina had been detached by the injection (Figure 1c ). Sections from the eye shown in Figure 1c that had been stained for LacZ prior to sectioning showed strong reaction product within RPE cells and among photoreceptor inner and outer segments ( Figure 1d ); in regions where there was less reaction product, it was limited to RPE cells (not shown).
When staining was carried out after sectioning, there was no reaction product in photoreceptors (not shown), indicating that RPE cells, but not photoreceptors, are transduced by this technique of nonviral gene transfer. The staining in Figure 1c is representative of four of the eyes that showed strong staining, but in two eyes the total area of LacZ-positive RPE cells was substantially less. The VMD2 gene, which encodes the protein Bestrophin, is specifically expressed in RPE cells and when mutated results in Best macular dystrophy. 36 The -585 to +38 bp 5 0 -upstream fragment of the VMD2 gene is sufficient to selectively drive reporter gene expression in RPE cells in transgenic mice, and placF/VMD2-LacZ plasmid was constructed by inserting this promoter fragment into placF to drive a LacZ gene. 35 In six of six eyes evaluated 3 days after subretinal injection of 0.5 mg of placF/VMD2-LacZ in 1 ml of aqueous medium combined with Ep10 V/mm, speckled staining was seen in the region of the injection (Figure 1e ) and sections showed strong staining in some, but not all, RPE cells (Figure 1f ). At 3 days after subretinal injection of 0.2 mg of pRc/ CMV-LacZ in 1 ml of medium containing 40% Lf, four of four eyes showed LacZ staining in RPE cells. Figure 1g shows a representative eye in which there was strong, but not uniform, staining throughout the region of the injection (Figure 1g ) that was very similar to that seen after electroporation. Localization of the staining on sections was also similar; staining was located primarily in RPE cells, and in areas with strongest staining, there was spread of staining among photoreceptor inner and outer segments (Figure 1h ), but in most areas it was limited to RPE cells.
After plasmid DNA transfer to RPE cells by electroporation or lipoplex, LacZ is detectable between 14 and 28 days and can be increased by repeated administration
In seven of seven eyes evaluated 14 days after subretinal injection of 0.5 mg of pRc/CMV-LacZ and Ep10 V/mm, there was still focal staining for LacZ throughout the area of the subretinal injection (Figure 2a ). Sections showed occasional stained RPE cells, and also thinning of the outer nuclear layer, suggesting there had been some death of photoreceptors (Figure 2b ). By 28 days after Ep10 V/mm, there was minimal focal staining remaining (Figure 2c ) in six of eight eyes evaluated, and no detectable staining in the other two eyes. Reinjection of 0.5 mg of pRc/CMV-LacZ followed by Ep10 V/mm on day 28 resulted in strong LacZ staining 3 days later in six of six eyes (Figure 2d ). Eight eyes evaluated 28 days after subretinal injection of 0.2 mg of pRc/CMV-LacZ/40% Lf showed sparse residual staining (four eyes) or no detectable staining (four eyes, Figure 2e) ; however, 3 days after repeat injection and 31 days after initial Gene transfer is achievable with lower concentrations of lipid carrier and lower power electroporation, which are less toxic to photoreceptors Subretinal injection of 0.5 mg of pRc/CMV-LacZ followed by Ep10 V/mm (Figure 2b) or injection of 0.2 mg of pRc/ CMV-LacZ/40% Lf (not shown) results in thinning of the outer nuclear layer after 2 weeks, indicating drop out of photoreceptors. Therefore, we explored whether injection of the same concentration of DNA with lower electroporation power, injection of less DNA with lower concentration of Lf, or use of another lipid carrier, Np, would be better tolerated. To assess retinal function, ERGs were performed 2 weeks after subretinal injection of 0.5 mg of pRc/CMV-LacZ, followed by electroporation with a power of 10, 6.7, or 3.4 V/mm. Control mice were given a subretinal injection of PBS and no electroporation. Electroporation with 10 or 6.7 V/mm, but not 3.4 V/mm, resulted in reduction in a-and b-wave amplitudes (Figure 3a and b) . Subretinal injection of (Figure 2g) , and 3 days after subretinal injection of 0.02 mg of pRc/CMV-LacZ/10% Np, five of five eyes showed strong, but not uniform, staining in RPE cells throughout the region of the injection (Figure 2h and i) . At 14 days after injection of 0.02 mg of pRc/CMV-LacZ/ 10% Np, there was still some focal staining for LacZ and no thinning of the outer nuclear layer in eight of ten eyes (Figure 2j and k) , and the other two eyes showed no detectable staining and a normal-appearing retina. This indicates that neither retinal structure nor function is disrupted by 10% Np (Figure 2j and k) .
At 3 days after subretinal injection of 0.5 mg of pRc/ CMV-LacZ combined with Ep3.4 V/mm, five of six eyes showed moderate focal staining for LacZ throughout the region of injection (Figure 2l) , and in two of two eyes evaluated after 14 days, there was still moderate focal staining (Figure 2m and n) .
To better evaluate the effects of 10% Np, Ep3.4 V/mm, and Ep10 V/mm on the morphology of retinal cells, some eyes were embedded in resin and 1 mm sections were stained with Toluidine Blue. In areas where there Figure  2p ), 14 days after the treatments the retina appeared normal; the outer nuclear layer had normal thickness and photoreceptor inner and outer segments were intact. In contrast, in areas where there had been subretinal injection of 0.5 mg of pRc/CMV-LacZ combined with Ep10 V/mm, there was substantial thinning of the retina with disruption of the outer nuclear layer and inner segments, and shortening of outer segments (Figure 2q) .
Transfer of plasmid DNA from the vitreous cavity into ganglion cells At 3 days after intravitreous injection of 0.5 mg of pRc/ CMV-LacZ followed by Ep10 V/mm, four of four eyes stained for LacZ showed faint blue reaction product visualized through the sclera and outer retina (Figure 4a , arrows). Sections showed strong staining of ganglion cell bodies and axons, and in sections through the optic nerve, stained axons were seen entering the nerve (Figure 4b and c) . Four of seven eyes showed intense staining remaining in occasional ganglion cells 14 days after injection (Figure 4d and e) . At 3 days after intravitreous injection of 0.2 mg of pRc/ CMV-LacZ/40% Lf, there was no detectable staining for LacZ in whole eyes (Figure 4f) or sections (not shown).
Transfer of plasmid DNA into extraocular muscles and connective tissue after periocular injections At 14 days after periocular injection of 10 ml containing 5 mg of pRc/CMV-LacZ followed by Ep10 V/mm, seven of seven eyes showed staining for LacZ in a rectus muscle (Figure 5a ). Staining within muscle fibers was very intense (Figure 5b, arrows) and there was also weaker staining of episcleral connective tissue (Figure  5b, arrowheads) . At 3 days after periocular injection of 10 ml containing 2 mg of pRc/CMV-LacZ/40% Lf, five of five eyes showed light staining for LacZ in connective tissue (Figure 5c and d) .
Discussion
Gene transfer is a valuable experimental tool and a promising approach for treatment of human diseases. In ocular research, gene transfer with viral vectors has been used to trace the lineage of cells during development, 37 explore the function of proteins in the retina and choroid, 38 express ribozymes to create somatic cell knockouts, and create animal models of disease. 39 In preclinical studies anticipating possible clinical usage, viral vectors have been used for gene replacement 10, 14, [40] [41] [42] and delivery of therapeutic proteins primarily for inhibition of neovascularization 11, 13, 17, 43 or prevention of retinal cell death. [44] [45] [46] As an alternative to viral-based gene transfer, nonviral vectors are easier to prepare and less prone to cause an immunologic reaction, but Electroporation has been demonstrated to substantially increase transduction efficiency of nonviral vectors in several tissues. It is most easily applied to readily accessible tissues such as the skin, and in the eye, it was first applied to the most accessible structure, the cornea. Recently, transduction of retinal ganglion cells was achieved in adult rats by intravitreous injection of plasmid DNA followed by electroporation with a hemisphere cathode on the cornea and a hemisphere anode with a groove that slides around the optic nerve on the posterior surface of the eye. 26 Electroporation of a plasmid containing the brain-derived neurotrophic factor (BDNF) gene using this approach provided sufficient expression of BDNF to significantly delay ganglion cell death after optic nerve transection. 27 In newborn rats or mice, electroporation with electrodes placed on each side of the head after subretinal injection of plasmid DNA resulted in widespread transduction of retinal cells, but the findings of Dezawa et al were questioned because there was little transduction of retinal cells when electroporation was carried out after intravitreous injection of DNA. 28 It was suggested that the basal laminae of the inner limiting membrane (ILM) might impede vector penetration. Our results confirm those of Dezawa et al 26 and demonstrate that the ILM is not a significant barrier to penetration of plasmid DNA.
Our study also demonstrates that it is possible to achieve strong transduction of RPE cells by subretinal injection of plasmid DNA followed by electroporation with the anode located on the back surface of the eye behind the site of injection and the cathode on the surface of the eye 1801 away. Transduction of the RPE was predominant when a plasmid containing a CMV/LacZ expression cassette was injected and exclusive when a plasmid containing a VMD2/LacZ expression cassette was injected. The ability to achieve efficient transduction of RPE cells in vivo provides a valuable tool for the study of gene regulation in RPE cells. This is because RPE cells tend to dedifferentiate when grown in culture and stop expressing many proteins that they normally express in vivo, including transcription factors, unless special culture conditions are used that make transfection difficult. 47 In addition, in vivo electroporation provides an alternative method for promoter analysis in the context of normal functioning cells that is more rapid and cost effective than traditional transgenic studies.
We have recently demonstrated that periocular injection of adenoviral vectors results in transduction of extraocular muscles and periocular connective tissue, and that secreted proteins as large as 75 kDa produced by these periocular tissues penetrate the sclera and exert biological effects in the choroid. 48, 49 In this study, we have shown that electroporation provides another means to achieve efficient periocular gene transfer. This should greatly facilitate the study of transcleral transport of Nonviral ocular gene transfer S Kachi et al proteins, since it will obviate the need to package expression cassettes for every protein of interest in adenoviral vectors.
We also investigated the feasibility of lipofection for ocular nonviral gene transfer using two commercially available lipid carriers, Lf and NP. Subretinal injection of lipoplex generated from mixing plasmid DNA with either Lf or NP resulted in transduction of RPE cells, but subretinal Lf resulted in decreased a-and b-wave ERG amplitudes and thinning of the outer nuclear layer by 14 days after injection. However, it is encouraging that retinal morphology and function remained normal after subretinal injection of 10% NP, while transduction of RPE cells was still achieved. Intravitreous injection of lipoplex resulted in no detectable staining and periocular injection resulted in faint staining in periocular connective tissue. The greater efficiency of RPE cell transduction compared to retinal ganglion cells or periocular tissue is probably due to the phagocytic activity of RPE cells.
Adenoviral vectors injected into the subretinal space efficiently transduce RPE cells, and transgene expression peaks within a few days and then declines and is generally undetectable by 1 month after injection. 50 Subretinal injection of plasmid DNA combined with electroporation or subretinal injection of lipoplex result in a similar expression profile. However, unlike adenoviral vectors, which are unable to substantially reinduce transgene expression by reinjection in rodents, electroporation and lipoplex injection are able to do so, providing an important advantage over adenoviral vectors.
It is clear that electroporation provides a useful means to achieve gene transfer to ocular tissues for animal experiments, but it is not yet clear if it can be used for ocular gene therapy in humans. The finding that low voltage pulses could achieve efficient and nontoxic gene transfer in animals suggests that it may be possible. Additionally, our data suggest that subretinal injection of lipoplex provides another alternative for ocular nonviral gene transfer, particularly to RPE cells that should be feasible for the treatment of humans. Additional studies are needed to further optimize both of these promising approaches.
